Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Ajax-Therapeutics"

1 News Found

Lilly buys Ajax Therapeutics for up to $2.3 billion to target rare blood cancers
Biopharma | April 28, 2026

Lilly buys Ajax Therapeutics for up to $2.3 billion to target rare blood cancers

Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026